Irinotecan Liposome Injection (Onivyde) - CPB - 0902 — CPB 0902 | AETNA Coverage Update

Aetna modified CPB 0902 for irinotecan liposome injection (Onivyde), effective February 25, 2026. Here's what billing teams need to do.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0902 governing Onivyde (HCPCS J9205) for commercial plans. The revision expands and clarifies medical necessity criteria across two tumor types — pancreatic adenocarcinoma and ampullary adenocarcinoma — including first-line NALIRIFOX regimen coverage and post-resection recurrence scenarios. If your oncology practice or infusion center bills J9205 with chemotherapy administration codes (CPT 96413–96417) or combination agents like oxaliplatin (J9263) or fluorouracil (J9190), this Aetna Onivyde coverage policy update directly affects your claim approval rates in 2026.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Irinotecan Liposome Injection (Onivyde) — CPB 0902
Policy Code	CPB 0902
Change Type	Modified
Effective Date	February 25, 2026
Impact Level	High
Specialties Affected	Medical Oncology, Hematology/Oncology, Infusion Therapy, GI Oncology
Key Action	Update prior authorization criteria and clinical documentation templates to reflect ECOG PS thresholds and NALIRIFOX regimen requirements before submitting new J9205 claims

---

Aetna Onivyde Coverage Criteria and Medical Necessity Requirements 2026

CPB 0902 covers J9205 (injection, irinotecan liposome, 1 mg) under two tumor-specific pathways. Both have strict performance status gates. Miss the documentation, and the claim denies — it's that simple.

Pancreatic Adenocarcinoma

This is where most of your Onivyde volume likely lives. Aetna recognizes four distinct coverage pathways for pancreatic adenocarcinoma.

First-line, locally advanced disease: Onivyde is medically necessary as first-line therapy, or as induction therapy followed by chemoradiation, for locally advanced disease without systemic metastases. The member must have good performance status (ECOG PS 0–1), good biliary drainage, and adequate nutritional intake. It must be given as part of the NALIRIFOX regimen — fluorouracil, leucovorin, liposomal irinotecan, and oxaliplatin.

First-line, metastatic disease: The same NALIRIFOX regimen qualifies for metastatic pancreatic adenocarcinoma with ECOG PS 0–1. Same biliary drainage and nutritional intake requirements apply.

Post-resection recurrence: This pathway is more nuanced and carries the highest claim denial risk if documentation is incomplete. Onivyde in combination with fluorouracil (J9190) and leucovorin (J0640) is covered for local recurrence in the pancreatic operative bed after resection, or for recurrent metastatic disease after resection, when the member meets ECOG PS 0–1 or intermediate PS (ECOG PS 2). Then one of three timing/prior therapy conditions must also be met:

#	Covered Indication Copy
1	Less than six months from completing primary therapy, previously treated with gemcitabine-based therapy
2	Less than six months from completing primary therapy, previously treated with fluoropyrimidine-based therapy that did not include irinotecan
3	Six months or more from completing primary therapy, as alternate systemic therapy not previously used

That six-month threshold is a hard line in this coverage policy. Document the completion date of primary therapy in every prior auth request.

Subsequent therapy for locally advanced or metastatic disease: Onivyde with leucovorin and fluorouracil is covered for disease progression if the member has ECOG PS 0–1 (with biliary drainage and nutritional criteria) or ECOG PS 2, and was previously treated with either gemcitabine-based therapy or fluoropyrimidine-based therapy without prior irinotecan.

Ampullary Adenocarcinoma

This is the less common indication but carries the same strict criteria. Aetna covers Onivyde for ampullary adenocarcinoma in two settings.

First-line NALIRIFOX: The member must have ECOG PS 0–1, good biliary drainage, and adequate nutritional intake. Coverage applies to pancreatobiliary and mixed type metastatic disease only.

Disease progression: Onivyde in combination with fluorouracil and leucovorin is covered when the member has ECOG PS 0–1 (same biliary and nutritional criteria) and pancreatobiliary and mixed type disease, after prior treatment with gemcitabine-based therapy, fluoropyrimidine-based therapy without prior irinotecan, or oxaliplatin-based therapy without prior irinotecan.

Continuation of Therapy

Once approved, Aetna considers continuation of J9205 medically necessary when there is no evidence of unacceptable toxicity or disease progression. Build this into your re-authorization workflow — Aetna will want documentation that the member is tolerating the regimen and not progressing.

One critical note: This policy does not apply to irinotecan hydrochloride (Camptosar). If your team bills for conventional irinotecan HCl under a different code, this bulletin does not govern that product.

---

Aetna Onivyde Exclusions and Non-Covered Indications

Aetna considers all indications not specifically listed in CPB 0902 as experimental, investigational, or unproven. That's a broad exclusion.

The policy does not cover Onivyde for intestinal-type ampullary adenocarcinoma in the NALIRIFOX first-line setting — only pancreatobiliary and mixed type qualify. Submit with the wrong histologic subtype documented, and you'll get a denial.

Any use outside of the ECOG performance status thresholds listed is also non-covered. A patient with ECOG PS 3 or 4 does not meet medical necessity under this policy, regardless of regimen. Document the ECOG score in your prior authorization request every time — not just at diagnosis, but at the time of each line of therapy.

---

Coverage Indications at a Glance

---

Aetna Onivyde Billing Guidelines and Action Items 2026

Copy Action Items

If you serve a high volume of GI oncology patients across multiple commercial payers, loop in your compliance officer to review how this CPB 0902 update aligns with any concurrent Cigna or UnitedHealthcare policy positions on Onivyde billing. These criteria don't always line up across payers.

---

CPT, HCPCS, and ICD-10 Codes for Irinotecan Liposome Injection Under CPB 0902

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9205	HCPCS	Injection, irinotecan liposome, 1 mg

Supporting HCPCS Codes (Combination Agents in Covered Regimens)

Chemotherapy Administration CPT Codes

Radiation Treatment Delivery CPT Codes

ICD-10-CM Diagnosis Codes

The full ICD-10 code set for CPB 0902 includes 1,018 codes. The source policy data excerpt does not enumerate the complete list here. Refer to the full CPB 0902 policy document for the complete ICD-10 code set, including the C24.x (ampulla of Vater) and C25.x (pancreas) ranges relevant to the covered indications.

The full ICD-10 code list for this policy is available in the complete CPB 0902 policy document at Aetna's clinical policy library. Map your primary pancreatic and ampullary ICD-10 codes against the covered indications table above before submitting claims under the updated CPB 0902 Aetna billing guidelines.

---